Immunogenicity of somatic mutations in human gastrointestinal cancers

Eric Tran(National Institutes of Health), Mojgan Ahmadzadeh(National Institutes of Health), Yong‐Chen Lu(National Institutes of Health), Alena Gros(National Institutes of Health), Simon Turcotte(National Institutes of Health), Paul F. Robbins(National Institutes of Health), Jared J. Gartner(National Institutes of Health), Zhili Zheng(National Institutes of Health), Yong F. Li(National Institutes of Health), Satyajit Ray(National Institutes of Health), John R. Wunderlich(National Institutes of Health), Robert Somerville(National Institutes of Health), Steven A. Rosenberg(National Institutes of Health)
Science
October 30, 2015
Cited by 727Open Access
Full Text

Abstract

It is unknown whether the human immune system frequently mounts a T cell response against mutations expressed by common epithelial cancers. Using a next-generation sequencing approach combined with high-throughput immunologic screening, we demonstrated that tumor-infiltrating lymphocytes (TILs) from 9 out of 10 patients with metastatic gastrointestinal cancers contained CD4(+) and/or CD8(+) T cells that recognized one to three neo-epitopes derived from somatic mutations expressed by the patient's own tumor. There were no immunogenic epitopes shared between these patients. However, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell receptor from CD8(+) TILs that targeted the KRAS(G12D) hotspot driver mutation found in many human cancers. Thus, a high frequency of patients with common gastrointestinal cancers harbor immunogenic mutations that can potentially be exploited for the development of highly personalized immunotherapies.


Related Papers